'Project continues to make excellent progress': Northern Ireland biotech firm secures grant extension for cancer treatment development project
Fusion Antibodies says the programme showcases Northern Ireland’s growing capabilities in advanced medicines and antibody development
Northern Ireland biotech firm Fusion Antibodies has hailed the extension of a grant from UK Research & Innovation (UKRI) and Invest NI which is being used to bring forward a cancer treatment project.


The InnovateUK Launchpad grant was awarded to the listed company in collaboration with Queen's University Belfast (QUB) to develop a humanised antibody targeting and activating the DR5 protein on cancer cells for the treatment of cancers resistant to other therapies.
The project aims to produce a clinic-ready therapeutic asset capable of being licensed to a third-party pharmaceutical or biotechnology company.
Given the progress made to date, UKRI has agreed to extend the project from its originally targeted completion date of 31 October 2026 to 31 December 2026.
Over the remaining months of the project, the DR5 humanised antibody and selected variants will undergo further pre-clinical evaluation in relevant cancer models.
Positive results are expected to support a patent application covering the antibody family and could lead to the creation of a licensable therapeutic asset for further development and commercialisation by an industry partner.
Dr Adrian Kinkaid, chief executive of Fusion which is based in Dunmurry, will present on the DR5 project at the ELRIG Drug Discovery conference in Boston, US, later this month.
He said: "I am delighted with the Grant support from InnovateUK enabling us to smoothly and successfully progress this project. It shows off several of our comprehensive capabilities in antibody development in a way which can benefit our clients and be used to support our marketing activities.
"It also demonstrates the value and utility of the Future Medicines Institute in supporting the further development of the capabilities to be found at Fusion in Belfast." Richard Buick, CSO of Fusion, added: "The DR5 project continues to make excellent progress. The latest variants have shown robust activity in induced cancer cell death assays, supporting their advancement into further studies.
"With the accelerated process to produce stable cell lines now in place, we are well positioned to deliver a comprehensive data package for the DR5 antibody asset as planned."
